Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

Exclusion Criteria

• •Known or suspected secondary hypertension
• •eGFR lower than 30 mL/min
• •Use of any other hypertension treatments during the enrollment and need for using the related treatments during the study phase
• •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. (i.e. valsartan, amlodipine, hydrochlorothiazide)
• •History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
• •Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days until the expected PD effect has returned to baseline, whichever is longer.Pregnant or nursing (lactating) women